JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. (Q38751230)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28255960%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

title

JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28255960%20AND%20SRC:MED&resulttype=core&format=json

Erratum to: JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.

4 April 2020

corrigendum / erratum

0 references

Erratum to: JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.

0 references

author

Daniella M Schwartz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28255960%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

author name string

Shubhasree Banerjee

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28255960%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Ann Biehl

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28255960%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Massimo Gadina

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28255960%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Sarfaraz Hasni

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28255960%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

publication date

1 April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28255960%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28255960%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

volume

77

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28255960%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28255960%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

page(s)

521-546

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28255960%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40265-017-0701-9

4 April 2020

exact match

0 references

cites work

Janus kinase inhibitors in autoimmune diseases

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Janus kinase inhibitors for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Tofacitinib for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Jaks and STATs: biological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

JAK1 Takes a FERM Hold of Type II Cytokine Receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

The Structural Basis for Class II Cytokine Receptor Recognition by JAK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Structural basis of recognition of interferon-α receptor by tyrosine kinase 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Treating inflammation with the Janus kinase inhibitor CP-690,550.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Structure, function, and regulation of STAT proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

The molecular regulation of Janus kinase (JAK) activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

A STAT inhibitor patent review: progress since 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Signaling via the CytoR/JAK/STAT/SOCS pathway: Emergence during evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Evolution of the JAK-STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Mechanism of activation of protein kinase JAK2 by the growth hormone receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Intracellular signal pathways: potential for therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Structural bases of unphosphorylated STAT1 association and receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

JAKs and STATs in immunity, immunodeficiency, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Mechanisms of Jak/STAT signaling in immunity and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Emancipation from transcriptional latency: unphosphorylated STAT5 as guardian of hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Dynamics and non-canonical aspects of JAK/STAT signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

The JAK-STAT pathway: impact on human disease and therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

JAK-mutant myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

JAK mutations in high-risk childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Inborn errors of human JAKs and STATs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

STAT2 deficiency and susceptibility to viral illness in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Gone fission: an asymptomatic STAT2 mutation elongates mitochondria and causes human disease following viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Signaling through IL-17C/IL-17RE is dispensable for immunity to systemic, oral and cutaneous candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

IL-22 increases the innate immunity of tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

21 January 2018

The hyper-IgE syndromes

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Somatic STAT3 mutations in large granular lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Cutting edge: Decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

JAK2 and STAT3 polymorphisms in a Han Chinese population with Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

STAT6 as an asthma candidate gene: polymorphism-screening, association and haplotype analysis in a Caucasian sib-pair study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Tofacitinib for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image atlas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Emerging drugs for psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Emerging drugs for the treatment of axial and peripheral spondyloarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Cytokines in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Promising biological therapies for ulcerative colitis: A review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Will novel oral formulations change the management of inflammatory bowel disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with ruxolitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Remission of recalcitrant dermatomyositis treated with ruxolitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Upcoming Therapeutic Targets in Cutaneous Lupus Erythematous

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Topical Ruxolitinib for the Treatment of Alopecia Universalis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Selective JAK inhibitors in development for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Small molecular compounds in development for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Baricitinib in Patients with Refractory Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

An update on the treatment of canine atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Progressive multifocal leukoencephalopathy associated with ruxolitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Decernotinib: A Next-Generation Jakinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Drug-drug interactions that interfere with statin metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Human mass balance, metabolite profile and identification of metabolic enzymes of [¹⁴C]ASP015K, a novel oral janus kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Novel Oral Therapies for Psoriasis and Psoriatic Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

STA-21, a promising STAT-3 inhibitor that reciprocally regulates Th17 and Treg cells, inhibits osteoclastogenesis in mice and humans and alleviates autoimmune inflammation in an experimental model of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Selective Inhibition of STAT3 with Respect to STAT1: Insights from Molecular Dynamics and Ensemble Docking Simulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Mutational switch of an IL-6 response to an interferon-gamma-like response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Cell-Permeable, Phosphatase-Stable Phosphopeptide Mimics Potently Inhibits Tyr641 Phosphorylation and Transcriptional Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Selective inhibition of the function of tyrosine-phosphorylated STAT3 with a phosphorylation site-specific intrabody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Pharmacologic inhibition of JAK-STAT signaling promotes hair growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

In search of magic bullets: the golden age of immunotherapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0701-9

Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis

21 January 2018

1 reference

12 December 2020

Absence of STAT1 disturbs the anticancer effect induced by STAT3 inhibition in head and neck carcinoma cell lines.

1 reference

12 December 2020

STATs: An Old Story, Yet Mesmerizing

1 reference

12 December 2020

The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis

1 reference

12 December 2020

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

1 reference

12 December 2020

Cytokines and their role in lymphoid development, differentiation and homeostasis

1 reference

12 December 2020

Tofacitinib versus methotrexate in rheumatoid arthritis

1 reference

12 December 2020

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

1 reference

12 December 2020

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

1 reference

12 December 2020

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

1 reference

12 December 2020

The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers

1 reference

12 December 2020

Growth hormone insensitivity associated with a STAT5b mutation

1 reference

12 December 2020

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

1 reference

12 December 2020

10.1007/S40265-017-0701-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28255960%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

4 April 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28255960%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

1 reference